Literature DB >> 18505775

Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable.

C Heesen1, J Böhm, C Reich, J Kasper, M Goebel, S M Gold.   

Abstract

Multiple sclerosis is a heterogeneous disease with varying clinical picture. There have been substantial efforts to develop outcome measurements for therapeutic interventions but very few studies have addressed the value of bodily functions from the patient perspective. In a randomly selected cohort of early (<5 years, n=84) and longer lasting disease courses (>15 years, n=82) patients we asked for a weighting of 13 bodily functions and compared results with actual disability as measured by the United Kingdom Disability Scale. Lower limb function was given the highest priority in both patient groups followed by visual functioning and cognition especially in longer lasting MS. Actual disability did not correlate with the given priorities indicating that experienced deficits do not influence the subjective ratings of bodily functions. These results underline that ambulation-focused scales in MS represent a key dimension from the patient perspective. Visual functioning should be taken more into account.

Entities:  

Mesh:

Year:  2008        PMID: 18505775     DOI: 10.1177/1352458508088916

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  129 in total

1.  Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world.

Authors:  Myla D Goldman; Robert W Motl; John Scagnelli; John H Pula; Jacob J Sosnoff; Diego Cadavid
Journal:  Neurology       Date:  2013-10-30       Impact factor: 9.910

2.  Evaluating walking in patients with multiple sclerosis: which assessment tools are useful in clinical practice?

Authors:  Francois Bethoux; Susan Bennett
Journal:  Int J MS Care       Date:  2011

3.  Step-length variability in minimally disabled women with multiple sclerosis or clinically isolated syndrome.

Authors:  Melanie Flegel; Katherine Knox; Darren Nickel
Journal:  Int J MS Care       Date:  2012

4.  Stride time variability as a marker for higher level of gait control in multiple sclerosis: its association with fear of falling.

Authors:  Gilles Allali; Magali Laidet; Stéphane Armand; Charlotte Elsworth-Edelsten; Frédéric Assal; Patrice H Lalive
Journal:  J Neural Transm (Vienna)       Date:  2016-04-22       Impact factor: 3.575

5.  Effects of lipoic acid on walking performance, gait, and balance in secondary progressive multiple sclerosis.

Authors:  Bryan D Loy; Brett W Fling; Fay B Horak; Dennis N Bourdette; Rebecca I Spain
Journal:  Complement Ther Med       Date:  2018-09-22       Impact factor: 2.446

6.  Altered visual and somatosensory feedback affects gait stability in persons with multiple sclerosis.

Authors:  Jordan J Craig; Adam P Bruetsch; Sharon G Lynch; Jessie M Huisinga
Journal:  Hum Mov Sci       Date:  2019-05-28       Impact factor: 2.161

7.  Visual pathway axonal loss in benign multiple sclerosis: a longitudinal study.

Authors:  Kristin M Galetta; Jennifer Graves; Lauren S Talman; Deacon J Lile; Elliot M Frohman; Peter A Calabresi; Steven L Galetta; Laura J Balcer
Journal:  J Neuroophthalmol       Date:  2012-06       Impact factor: 3.042

Review 8.  Fampridine Prolonged Release: A Review in Multiple Sclerosis Patients with Walking Disability.

Authors:  Esther S Kim
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

9.  Gait changes with balance-based torso-weighting in people with multiple sclerosis.

Authors:  Anna-Maria Gorgas; Gail L Widener; Cynthia Gibson-Horn; Diane D Allen
Journal:  Physiother Res Int       Date:  2014-06-14

10.  Color vision impairment in multiple sclerosis points to retinal ganglion cell damage.

Authors:  E J Lampert; M Andorra; R Torres-Torres; S Ortiz-Pérez; S Llufriu; M Sepúlveda; N Sola; A Saiz; B Sánchez-Dalmau; P Villoslada; Elena H Martínez-Lapiscina
Journal:  J Neurol       Date:  2015-08-11       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.